FSTL3 is a prognostic biomarker in gastric cancer
DSCAM-AS1 and miR-122-5p. Although there has been a small amount of research on FSTL3, the exact mechanism by which FSTL3 functions as an oncogene remains unclear to date. Therefore, in the present study, we aimed to explore the molecular mechanism of FSTL3 involvement in gastric carcinogenesis and development, and to evaluate its value as a prognostic biomarker and potential therapeutic target for GC. Materials and Methods Cell Culture AGS (moderately differentiated GC cells), HGC-27 (undifferentiated GC cells), GES-1 (healthy gastric epithelial cells), and THP-1 cells (human monocytic cel...